54 search results for: chronic inflammation

The Role of IL-4 and IL-13 in CSU Pathogenesis
Type 2 Inflammation
The Role of IL-4 and IL-13 in CSU Pathogenesis
interactivity

Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

View more
Assessment of Smell Loss in CRSwNP Interactive Infographic
Rhinology
Assessment of Smell Loss in CRSwNP Interactive Infographic
interactivity

Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.

View more
ERS 2026
Congress
5
September
2026
Congress
ADVENT at ERS 2026

Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.

World Anosmia Day 2026
On Demand
World Anosmia Day 2026

Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

Type 2 <b>Inflammation</b>: Links With Severe Uncontrolled CRSwNP
Rhinology
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

View more
Impact of Exacerbations in COPD
Type 2 Inflammation
Impact of Exacerbations in COPD
expert video

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

View more
Exacerbations Lead to Worsening Lung Function
Type 2 Inflammation
Exacerbations Lead to Worsening Lung Function
expert video

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

View more
UEG Upcoming Events Carousel Thumbnail
Congress
5
October
2025
Congress
ADVENT at UEG WEEK 2025 | Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care

Join Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, for an educational symposium as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression.

EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​
Congress
31
May
2024
Congress
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

UEG Upcoming Events Carousel Thumbnail
On Demand
Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care

Join leading experts in EoE, Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression. They review the latest clinical evidence on therapeutic management and share insights from their own practice to support shared decision-making in the long-term care of EoE.